Jun 28, 2021 / 12:30PM GMT
Operator
Dear, ladies and gentlemen, welcome to the conference call of Idorsia. As ordered from this request, this conference will be recorded. (Operator Instructions)
May I now hand you over to Andrew Weiss, who will lead you through this conference. Please go ahead.
Andrew C. Weiss - Idorsia Ltd - Senior VP and Head of IR & Corporate Communications
Thank you, Olie. Good morning, good afternoon, everyone, and welcome to today's Idorsia call on the launch of the Phase III trial for selatogrel and suspected AMI.
Before I jump, I hand over the microphone to our participants. I do need to remind everybody that we will be making forward-looking statements in this call.
So with me on the call today, Slide 3, please, are our CEO, Jean-Paul Clozel; our Chief Scientific Officer, Martine Clozel; and our Head of Global Clinical Development, Guy Braunstein.
To make his introductory comments, I hand over to Jean-Paul. Thank you.
Jean-Paul Clozel - Idorsia Ltd - CEO & Director
Idorsia Ltd To Discuss Phase 3 Program -Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
